|
1
|
Singh D, Upadhyay G, Srivastava RK and
Shankar S: Recent advances in pancreatic cancer: Biology,
treatment, and prevention. Biochim Biophys Acta. 1856:13–27.
2015.PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boatright KM, Renatus M, Scott FL,
Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP,
Green DR, et al: A unified model for apical caspase activation. Mol
Cell. 11:529–541. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arlt A, Müerköster SS and Schäfer H:
Targeting apoptosis pathways in pancreatic cancer. Cancer Lett.
332:346–358. 2013. View Article : Google Scholar
|
|
5
|
Ashkenazi A: Targeting death and decoy
receptors of the tumour-necrosis factor superfamily. Nat Rev
Cancer. 2:420–430. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Pietro R and Zauli G: Emerging
non-apoptotic functions of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol.
201:331–340. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu H, Zeng F, Zhang M, Huang F, Wang J,
Guo J, Liu C and Wang H: Emerging landscape of cell penetrating
peptide in reprogramming and gene editing. J Control Release.
226:124–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joseph SC, Blackman BA, Kelly ML, Phillips
M, Beaury MW, Martinez I, Parronchi CJ, Bitsaktsis C, Blake AD and
Sabatino D: Synthesis, characterization, and biological activity of
poly(arginine)-derived cancer-targeting peptides in HepG2 liver
cancer cells. J Pept Sci. 20:736–745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang W, Zhang N, Zhao T, Liu M, Zhang T
and Li D: Inhibition of tumor growth by polyarginine-fused mutant
cytosine deaminase. Appl Biochem Biotechnol. 175:1633–1643. 2015.
View Article : Google Scholar
|
|
10
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cha SS, Song YL and Oh BH: Specificity of
molecular recognition learned from the crystal structures of TRAIL
and the TRAIL:sDR5 complex. Vitam Horm. 67:1–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alhakamy NA, Dhar P and Berkland CJ:
Charge Type, Charge Spacing, and Hydrophobicity of Arginine-Rich
Cell-Penetrating Peptides Dictate Gene Transfection. Mol Pharm.
13:1047–1057. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fujita T, Furuhata M, Hattori Y, Kawakami
H, Toma K and Maitani Y: High gene delivery in tumor by
intratumoral injection of tetraarginine-PEG lipid-coated
protamine/DNA. J Control Release. 129:124–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Papaneophytou CP and Kontopidis GA:
Optimization of TNF-α overexpression in Escherichia coli using
response surface methodology: Purification of the protein and
oligomerization studies. Protein Expr Purif. 86:35–44. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eiteman MA and Altman E: Overcoming
acetate in Escherichia coli recombinant protein fermentations.
Trends Biotechnol. 24:530–536. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ozawa F, Friess H, Kleeff J, Xu ZW,
Zimmermann A, Sheikh MS and Büchler MW: Effects and expression of
TRAIL and its apoptosis-promoting receptors in human pancreatic
cancer. Cancer Lett. 163:71–81. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stadel D, Mohr A, Ref C, MacFarlane M,
Zhou S, Humphreys R, Bachem M, Cohen G, Möller P, Zwacka RM, et al:
TRAIL-induced apoptosis is preferentially mediated via TRAIL
receptor 1 in pancreatic carcinoma cells and profoundly enhanced by
XIAP inhibitors. Clin Cancer Res. 16:5734–5749. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stuckey DW and Shah K: TRAIL on trial:
Preclinical advances in cancer therapy. Trends Mol Med. 19:685–694.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maksimovic-Ivanic D, Stosic-Grujicic S,
Nicoletti F and Mijatovic S: Resistance to TRAIL and how to
surmount it. Immunol Res. 52:157–168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Humphreys RC and Halpern W: Trail
receptors: Targets for cancer therapy. Adv Exp Med Biol.
615:127–158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ashkenazi A, Holland P and Eckhardt SG:
Ligand-based targeting of apoptosis in cancer: The potential of
recombinant human apoptosis ligand 2/Tumor necrosis factor-related
apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol.
26:3621–3630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vogler M, Dürr K, Jovanovic M, Debatin KM
and Fulda S: Regulation of TRAIL-induced apoptosis by XIAP in
pancreatic carcinoma cells. Oncogene. 26:248–257. 2007. View Article : Google Scholar
|
